Jilin Province Great Great Pharmaceutical Co. LTD

Jilin Province Broadwell Pharmaceutical Co., LTD. Welcome you!

Service hotline:+86-431-85639055

博大伟业
imgboxbg

HEALTH SCIENCE

Your current location:
Homepage
/
/
/
Relaisen-a new choice for eradicating Helicobacter pylori

Relaisen-a new choice for eradicating Helicobacter pylori

  • Categories:Stomach healthy
  • Author:
  • Origin:
  • Time of issue:2020-12-03
  • Views:0

(Summary description)

Relaisen-a new choice for eradicating Helicobacter pylori

(Summary description)

  • Categories:Stomach healthy
  • Author:
  • Origin:
  • Time of issue:2020-12-03
  • Views:0
Information

  After the discovery of Helicobacter pylori (Hp) in the etiology of the gastroduodenum, the treatment of peptic ulcer has been completely changed. The cure of Hp infection can significantly reduce the recurrence rate of gastritis and peptic ulcer, and it can also Reduce many complications.

  Boda Weiye Ruilaisheng (Polyprezinc Granules) is a chelate composed of zinc and L-carnosine. It is a mucosal protective agent with a unique mechanism of action, which mediates anti-ulcer effects by protecting the gastric mucosa. Polyprezinc has antibacterial, anti-urease and anti-adhesion properties against Hp, and is an effective drug for removing Hp. Compared with dual therapy, the triple therapy of lansoprazole, amoxicillin and clarithromycin (LAC) is more effective in eradicating Hp. In order to seek a simpler and more effective treatment plan, on the basis of the original triple therapy (LAC) plus polyprezinc, will it increase the eradication rate of Hp? Let’s look at the following research.

  1.1 Patients

  A total of 66 patients were enrolled, 47 males and 19 females, with an average age of 48.5 years, 28 of which were peptic ulcer (PU) and 38 were non-ulcer dyspepsia (NUD).

  Inclusion criteria: Endoscopically diagnosed patients with Hp-related NUD and PU;

  Exclusion criteria: under 18 years of age; pregnant; adverse reactions to penicillin, macrolides or proton pump inhibitors; severe comorbid diseases; Hp eradication or anticoagulant treatment.

  1.2 Upper gastrointestinal endoscopy

  At least 3 tissue biopsy specimens were taken from each patient, respectively from the pylorus and the gastric antrum within 2±3cm of the gastric body, all operated by the same endoscopist. The specimens were subjected to rapid urease test, Hp culture and histological examination.

  1.3 Hp diagnosis

  At least 3 tissue biopsy specimens were taken from each patient, respectively from the pylorus and the gastric antrum within 2±3cm of the gastric body, all operated by the same endoscopist. The specimens were subjected to rapid urease test, Hp culture and histological examination.

  1.4 Test method

  66 patients were randomly divided into two groups, LAC group (n=31): Lansoprazole (30 mg bd) + amoxicillin (500 mg bd) + clarithromycin (400 mg bd) for 7 days; LACP group (n=35): LAC regimen + Polyprezinc (150 mg bd) for 7 days.

  1.5 Transmucosal potential difference

  In the intention-to-treat analysis, shedding patients are considered as failure to eradicate Hp. Using Student’t test and Chi-square test to compare the demographic and clinical characteristics of the two groups, P<0.05 was statistically significant.

  Experimental results and analysis

  2.1 Polyprezinc significantly improves Hp eradication rate

  31 cases in the LAC group (15 cases in PU, 16 cases in NUD). There were 35 cases in the LACP group (13 cases in PU, 22 cases in NUD). Sixty-six patients were included for the Hp infection intention-to-treat analysis, and 5 patients did not complete the treatment: 2 patients in the LAC group did not undergo follow-up endoscopy; 1 patient in the LAC group and 2 patients in the LACP group stopped treatment due to severe diarrhea, and were finally included in 61 Protocol analysis was performed on two patients. According to the completion treatment analysis method, after LAC treatment, 24 out of 28 patients had Hp radical cure (85.7%); in the LACP group, 33 out of 33 patients had Hp radical cure (100%, P<0.05). According to the intention-to-treat analysis method, 24 of the 31 patients in the LAC group were cured (77.4%), while 33 of the 35 patients in the LACP group were cured (94.3%, P<0.05). It can be seen that the quadruple therapy with polyprezinc significantly improves the eradication rate of Hp.

  2.2 Polyprezinc is well tolerated and drug compliance

  Gavage of NH2Cl (120mM) caused multiple band-like lesions in the gastric mucosa, with an injury score of 128.2±19.6mm². Indomethacin (5mg/kg) and L-NAME (10mg/kg) had no effect on the injury, but the sensory afferent nerve block was significantly worsened after capsaicin pretreatment (Figure 2). dmPGE2 (10μg/kg), norfloxacin-3 (3mg/kg) and capsaicin (30mg/kg) can significantly prevent gastric mucosal damage.

  Discuss

  Research has shown that, compared with triple therapy, quadruple therapy with polyprezinc can significantly increase the eradication rate of H. pylori and the patient's tolerance and drug compliance are good.

  Boda Weiye Ruilaisheng (Polyprezinc Granules) has become a new choice for quadruple therapy and a new gospel for patients with refractory Helicobacter pylori!

Scan the QR code to read on your phone

Jilin Province Great Great Pharmaceutical Co. LTD

Service hotline

+86-431-81158731

CONTACT US

Jilin Province Great Great Pharmaceutical Co. LTD

Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD

Liaoyuan Production Base: No. 158 Fortune Road, Liaoyuan Economic Development Zone, Jilin Province

Tel:+86-437-6998023

Changchun R&D Center: No. 3786 Juye Street, Jingyue Development Zone, Changchun City, Jilin Province
Tel:+86-431-81158731(Marketing center)

Tel:+86-431-81158756(Research and development center)

Beijing Office: Room 901, Building F, Kaixuan City, 170 Beiyuan Road, Chaoyang District, Beijing
Tel:+86-10-58236233

Medication consultation, feedback on medication adverse reaction, and user complaint telephone:0437-5029815 

NO PUBLIC

Jilin Province Great Great Pharmaceutical Co. LTD

Scan and follow the official official account

Copyright © Jilin Province Great Great Pharmaceutical Co. LTD        吉ICP备20002630号

Website construction:300.cn Changchun   management     

Jilin Province Great Great Pharmaceutical Co. LTD